Biodesix Inc (BDSX) stock

BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30

$9.88+0.09 (+0.92%)

Close on Nov 13, 2026Market cap $104.25MP/E –Yield –

Biodesix r&d expenses

Research and development expenses are spending on new products and technology.

Biodesix's R&D Expenses for the twelve months ending Sep 30, 2026 was $12.28M, up 6.4% year over year. For fiscal 2025 it was $12.00M, up 25.5% from the year before. The highest annual figure on record is $13.10M in fiscal 2022.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$12.00M	+25.5%
FY2024	Dec 31, 2024	$9.56M	-4.3%
FY2023	Dec 31, 2023	$9.99M	-23.8%
FY2022	Dec 31, 2022	$13.10M	+2.4%
FY2021	Dec 31, 2021	$12.79M	+18.2%
FY2020	Dec 31, 2020	$10.82M	+3.3%
FY2019	Dec 31, 2019	$10.47M	–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$2.99M	+0.1%
Q2 FY2026	Jun 30, 2026	$3.14M	-4.1%
Q1 FY2026	Mar 31, 2026	$3.29M	+14.5%
Q4 FY2025	Dec 31, 2025	$2.87M	+18.9%
Q3 FY2025	Sep 30, 2025	$2.99M	+17.5%
Q2 FY2025	Jun 30, 2025	$3.27M	+27.8%
Q1 FY2025	Mar 31, 2025	$2.87M	+40.7%
Q4 FY2024	Dec 31, 2024	$2.41M	+27.8%
Q3 FY2024	Sep 30, 2024	$2.55M	+31.4%
Q2 FY2024	Jun 30, 2024	$2.56M	-12.1%
Q1 FY2024	Mar 31, 2024	$2.04M	-37.3%
Q4 FY2023	Dec 31, 2023	$1.89M	-47.0%
Q3 FY2023	Sep 30, 2023	$1.94M	-34.7%
Q2 FY2023	Jun 30, 2023	$2.91M	-13.4%
Q1 FY2023	Mar 31, 2023	$3.25M	+1.4%
Q4 FY2022	Dec 31, 2022	$3.57M	+25.0%
Q3 FY2022	Sep 30, 2022	$2.97M	-9.8%
Q2 FY2022	Jun 30, 2022	$3.36M	+1.1%
Q1 FY2022	Mar 31, 2022	$3.21M	-3.5%
Q4 FY2021	Dec 31, 2021	$2.85M	-8.1%
Q3 FY2021	Sep 30, 2021	$3.29M	+21.7%
Q2 FY2021	Jun 30, 2021	$3.32M	+57.7%
Q1 FY2021	Mar 31, 2021	$3.32M	+14.5%
Q4 FY2020	Dec 31, 2020	$3.11M	+24.1%
Q3 FY2020	Sep 30, 2020	$2.71M	+14.7%
Q2 FY2020	Jun 30, 2020	$2.11M	–
Q1 FY2020	Mar 31, 2020	$2.90M	–
Q4 FY2019	Dec 31, 2019	$2.50M	–
Q3 FY2019	Sep 30, 2019	$2.36M	–